We conducted in vivo and in vitro experiments to evaluate the characterization, brain distribution, and therapeutic efficiencies of Tf-Pep63-Lip in an early AD mouse model, including the underlying mechanism of Pep63-mediated neuroprotection and PA-mediated Aβ clearance effects. This evidence concerns the gene TF and Alzheimer disease.